The US Food and Drug Administration (FDA) has approval for 鈥檚 Pemazyre (pemigatinib) to treat adults with relapsed or refractory (r/r) myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.
The approval was based on findings from the multicentre, open-label, single-arm Phase II FIGHT-203 clinical trial that assessed the safety and efficacy of Pemazyre in 28 adult patients with r/r MLNs with FGFR1 rearrangement.
According to the results, the treatment offered a complete response (CR) rate of 78% in patients with chronic phase in the marrow with or without extramedullary disease (EMD).
In the trial, the median time to response of CR was 104 days and the median duration of CR was not attained.
In people with blast phase in the marrow irrespective of EMD status, two subjects attained a CR.
One subject among those with EMD only attained a CR.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataFor all the trial subjects, a complete cytogenetic response rate of 79% was reported.
The regulatory agency analysed the supplemental New Drug Application (sNDA) for Pemazyre to treat r/r MLNs with FGFR1 rearrangement in adults under Priority Review.
Pemazyre is a selective fibroblast growth factor receptor (FGFR) inhibitor for various indications.
Apart from the latest indication, the therapy is intended to treat adult patients with r/r priorly treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangements.
CEO Herv茅 Hoppenot said: 鈥淭he approval of Pemazyre represents an important treatment advancement for people living with MLNs with FGFR1 rearrangement who currently have limited treatment options.
鈥淭hese are complex hematologic malignancies with a range of presentations, and this approval highlights Incyte鈥檚 continued leadership and commitment to advancing care for patients with rare blood cancers.鈥�
A rare and aggressive type of blood cancer, MLNs with FGFR1 rearrangement affect less than one in 100,000 people in the US.
In July this year, the company received FDA approval for Opzelura (ruxolitinib) cream 1.5% as a topical treatment for nonsegmental vitiligo in adults and paediatric patients aged 12 years and above.
